|
COPYRIGHT 2001 The Boston Globe
Byline: Ronald Rosenberg
Mar. 16--Genentech Inc. filed a lawsuit yesterday challenging Genzyme Corp.'s interpretation of a 9-year-old agreement under which Genzyme contends it would be owed royalties from Genentech's clot-busting agent TNKase.
"We are very surprised that they have sued us," said Thomas J. DesRosier, Genzyme's senior vice president and chief patent counsel. "TNKase is a second-generation drug that, under a 1992 settlement beween us, calls for them to pay us royalties. But I did not...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
